The hope that Pfizer and its competitor Moderna have here is that they can really compress the production timeline for a shot. The company wants to add 25 billion in revenue just via MNA through 2023. Wall Street doesn't feel too bullish about Pfizer right now the stock is down 25% to date this year.
Bloomberg News Legal Reporter Jef Feeley explains why Elon Musk is reviving his original deal to buy Twitter at the price of $54.20 a share. Bloomberg Balance of Power Anchor David Westin discusses Micron's plan for a $100 billion for semiconductor factory in New York. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Health Care Reporter Riley Griffin provide the details of Riley's Businessweek Magazine story Pfizer Needs to Prove That It’s Ready to Move On From Covid-19. Stewart Glickman, Head of Energy Research at CFRA, talks about investing in energy firms in this inflationary environment. And we Drive to the Close with Sylvia Jablonski, CEO at Defiance ETFs.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.